肺癌基因组检测市场：2025-2032年全球预测（按技术、检测类型、应用和最终用户划分）

预计到 2032 年，肺癌基因组检测市场将成长至 20.7 亿美元，复合年增长率为 8.56%。

关键市场统计数据
基准年 2024	10.7亿美元
预计年份：2025年	11.6亿美元
预测年份 2032	20.7亿美元
复合年增长率 (%)	8.56%

技术进步和临床整合正在重新定义肺癌基因组检测，并塑造治疗路径。

肺癌基因组检测目前处于临床紧迫性和技术能力的交汇点，正在重塑诊断、治疗决策和转化研究。随着分子资讯日益成为标靶治疗治疗和免疫疗法适用性的决定因素，临床医生和实验室正在积极采用基因组检测，并从组织学驱动的治疗路径转向基于精准医学的治疗路径。这促成了以往各自独立的学科（病理学、分子生物学、生物资讯学和临床肿瘤学）的融合，从而提供整合的治疗路径，缩短标靶治疗时间，并实现更精准的患者分层。

此外，检测格局正从单基因检测发展到多基因panel和全面的基因组分析，从而能够捕捉可操作的突变、拷贝数变异和复杂的基因组特征。与基于组织的检测方法相辅相成，微创替代方法（例如血液检测）正在加速诊断流程，并改善患者持续监测的可及性。同时，监管政策的明确性、支付方的参与以及临床指南的更新也日益趋于一致，基因组检测正成为许多肿瘤治疗网络中标准治疗的核心组成部分。这些趋势正在塑造一种新的商业环境，其中技术差异化、证据生成和营运韧性将决定哪些机构主导下一波临床和商业性应用浪潮。

定序、液态生物检体和数位生物资讯学的进步正在融合，迅速改变肺癌诊疗的诊断流程和病患管理方式。

肺癌基因组检测领域正经历多项变革，主要得益于检测技术、数据分析和诊疗模式的进步。其中最显着的是，次世代定序已从高成本、以研究为导向的工作流程，发展成为更有效率、经临床检验的平台，支援全EXOME和全基因组定序以及标靶定序panel等多种覆盖方式。这项进步使临床医生能够检测罕见突变和全面的基因组特征，同时也使实验室能够优化检测通量和缩短结果週转时间。

同时，涵盖循环性肿瘤细胞和循环肿瘤DNA的液态生物检体调查方法正从辅助工具转变为诊断和监测策略的重要组成部分。这些检测方法提供了一种微创手段，可以捕捉肿瘤异质性，并监测治疗反应和新抗药性的出现。此外，即时聚合酵素链锁反应（PCR）和萤光杂合反应（FISH）在特异性和快速生物标记检测方面仍然发挥关键作用，尤其是在监管和支付框架支持成熟方法的情况下。

同时，数位医疗和人工智慧驱动的生物资讯学日益成熟，能够支持自动化突变检测、临床註释和决策支持，从而减少解读瓶颈，并实现跨不同临床环境的可扩展报告。监管机构正在调整伴随诊断和复杂基因组检测的指导方针，而支付方则在加强对临床效用和基于价值的报销路径的评估。这些变化共同建构了一个更整合、数据丰富的生态系统，重视证据产生、互通性和营运灵活性。

近期关税引发的供应链压力如何重塑基因组诊断的采购、生产策略和商业性模式

近期各国政策制定者对关税的调整，使得诊断生态系统更重视供应链韧性与筹资策略。由于基因组检测依赖全球供应链来获取试剂、定序设备、塑胶耗材和专用微流体组件，关税导致的成本增加将波及实验室运作、试剂采购週期以及资本设备购置决策。因此，实验室和诊断服务提供者必须重新评估供应商合约、库存策略和资本投资计划，以确保服务的连续性和可接受的检测结果週转时间。

为此，多方相关人员正在探索替代采购管道和本地製造伙伴关係，以降低进口关税和运输波动带来的风险。采购团队正在协商长期供应协议，并优先选择生产地点多元化的供应商，以减少单一来源风险。同时，诊断试剂开发商正在加快研发可减少试剂用量并允许替换关税敏感成分的检测方案，从而减轻进口关税对其营运的影响。

从临床角度来看，持续的成本压力可能会延缓某些医疗机构采用昂贵且全面的检测方法，除非有支付方的医保覆盖或打包合约来抵销成本。这促使实验室和设备製造商加大对卫生经济学证据和真实世界效用研究的投入，以证明成本效益并支持基于价值的合约的製定。整体而言，关税压力是推动策略转型、供应链多元化、在地化生产和商业性永续的检测设计的重要催化剂。

针对特定细分市场的洞察，展示了技术选择、检体模式、临床应用和最终用户能力如何相互作用，从而决定采用路径和价值提案。

详细的細項分析揭示了不同技术、检测类型、应用领域和最终用户类别所呈现的截然不同的应用模式，从而影响市场机会和投资重点。在技​​术方面，检测方法多种多样，从萤光原位杂合反应和微阵列平台到即时聚合酵素链锁反应和桑格定序，不一而足。然而，次世代定序（NGS）已成为一项核心技术，其配置多种多样，包括用于精准检测可操作突变的靶向定序panel、用于全面分析编码区的全EXOME定序以及用于最广泛突变检测和结构解析的全基因测序。每种配置在灵敏度、覆盖范围、週转时间和结果解读复杂度方面各有优劣。

从检测类型来看，此领域可分为液态生物检体和组织切片检查两种方式。液态生物检体包括循环性肿瘤细胞(CTC) 和循环肿瘤 DNA (ctDNA) 检测，具有微创取样和连续监测的极佳可行性。组织切片检查对于组织病理学评估至关重要，包括细针穿刺以及用于免疫组织化学和分子检测的传统组织切片。这两种取样技术在诊断流程中通常发挥互补作用，最佳检测顺序取决于特定的诊断管理方案。

在应用方面，检测可用作伴随诊断，直接指导治疗方案的选择；用作预测性检测，预测治疗反应；用作预后检测，实现预后预测；以及用作治疗监测，检测抗药性和復发。检测的普及程度取决于临床环境、实证依据和支付方的合作情况。最终用户包括推动检测方法检验和转化研究的学术和研究机构、提供大规模临床检测并管理患者流程的医院和诊断实验室，以及依赖强大的基因组表征来支持药物发现、伴随诊断合作和患者选择策略的製药和生物技术公司。这些群体之间的相互作用凸显了客製化价值提案涵盖了从高通量临床检测服务到用于药物发现的特定转化平台等各个方面。

影响技术采纳、报销参与和策略合作的区域采纳趋势和基础设施因素

区域趋势对技术应用、监管协调和商业策略产生了重大影响，美洲、欧洲、中东和非洲以及亚太地区呈现出截然不同的模式。在美洲，由学术机构、综合医疗系统和诊断创新者组成的强大生态系统推动了先进基因组分析和液态生物检体检测的早期临床应用。该地区的报销框架和大规模临床研究支持将伴随诊断整合到治疗路径中，领先的实验室和商业合作伙伴也持续投资于平台扩充性和临床检验计画。

欧洲、中东和非洲地区的情况更为复杂，多个国家法律规范较强，但医疗资源取得和基础设施水准却参差不齐。欧洲各国正努力协调伴随诊断的临床证据和监管要求，合作研究网络也促进了多中心合作，以应对临床效用的挑战。然而，在中东和北非地区的某些区域，由于实验室能力和报销障碍，医疗资源取得仍然有限，因此需要重点发展区域卓越中心和公私合营，以扩大先进检测服务的覆盖范围。

亚太地区临床和生产能力的快速扩张引人注目，但其支付方格局呈现出多元化的特征。在当地诊断产业蓬勃发展和基因组学领域巨额投资的推动下，多个市场对定序平台和液态生物检体检测的采用率均显着提高。然而，不同地区的采用率存在差异，一些具有战略意义的企业通常会将集中式高复杂度检测中心与分散式检体采集和数位化报告系统相结合，以克服地域和资源方面的限制。这些区域差异凸显了打入市场策略的必要性，这些策略必须充分考虑当地的监管流程、报销机制和医疗基础设施。

定序仪製造商、试剂供应商、诊断实验室和生物製药合作伙伴如何协调策略，以实现临床应用和商业性差异化

肺癌基因组检测价值链的竞争主要集中在以下几类公司之间：提供定序平台、检测试剂、综合诊断服务和临床解读解决方案的公司，以及将检测与治疗方案结合的临床实验室和诊断开发公司。领先的仪器供应商正致力于推进先进的平台蓝图，重点关注通量、运行成本和整合分析；而试剂和试剂套件供应商则在稳健性、批间一致性和临床检验方案方面展开竞争，这些方案能够简化监管申报和实验室认证流程。

诊断实验室和专科服务提供者正利用垂直整合，提供从检体接收到临床报告的端到端服务，这些服务通常辅以专有的生物资讯学流程和精心整理的突变资料库。製药和生物技术公司优先考虑能够提供快速且可重复的基因组表征的合作伙伴，以帮助筛选临床试验的患者并共同开发伴随诊断。为了拓展检测产品组合、增强地理覆盖范围并加速诊断适应症的上市速度，企业通常会采取合作、分销协议和定向收购等策略措施。

为了保持竞争力，各机构正加大投入，致力于产生真实世界证据、加强与支付方的合作以及提升与电子健康记录的互通性，以证明其临床效用并推动临床医生采用。此外，那些提供扩充性的云端解读工具并坚持高标准的临床检验的公司，更有利于满足来自集中式参考实验室和分散式医院网路的需求。

为加强供应链韧性、加快证据产生以及确保与支付方和合作伙伴协作以实现永续成长，提出切实可行的建议

产业领导者应优先采取一系列切实可行、基于实证的行动，以在应对技术复杂性、政策变化和市场压力的同时，以实现临床和商业性价值。首先，应推进供应链多元化，并对关税敏感的试剂和耗材采取本地化生产或第二供应商采购策略，以降低单点故障风险并稳定采购成本。同时，应投资优化检测方法，最大限度地减少试剂用量并简化工作流程，从而保持获利能力和韧性。

第二，加速临床检验和真实世界证据项目，以证明其临床效用和卫生经济价值。可靠的结果数据集将加强健保谈判，并有助于将全面的基因组分析纳入标准治疗路径。第三，扩展生物资讯学和人工智慧驱动的解读能力，以缩短报告週转时间，提高变异分类的一致性，并实现可扩充性的临床决策支持，使其能够与电子健康系统整合。第四，与支付方建立联繫，探索将医保报销与可证实的临床结果挂钩的价值基本契约，从而协调各相关人员的奖励。

第五，我们将与製药开发商建立策略联盟，共同开发伴随诊断试剂，并透过生物标记驱动的筛检招募临床实验参加者。最后，我们将根据不同地区优化市场进入策略，使产品声明和证据包符合当地监管要求，并部署混合模式，将集中式高复杂度检测与精简的检体物流和远端报告相结合，以扩大市场准入范围。

采用透明、多方面的调查方法，结合与专家的直接对话和系统的证据审查，以确保得出严谨且具有可操作性的研究结果。

本分析所依据的研究采用了一种多方面的方法，结合了初步的定性研究和系统的二手研究，建构了一个稳健的、三角验证的证据基础。初步研究包括对临床实验室主任、分子病理学家、医保报销专家、诊断试剂开发人员和药物研发负责人进行结构化访谈，并辅以专家专题研讨会，以检验检测应用方面的新兴趋势和实际挑战。这些工作深入分析了实验室工作流程、采购趋势以及监管和收费变化对营运的影响。

二次研究包括对监管指导文件、临床实践指南、同行评审的关于检测性能和效用的文献以及公司披露的战略重点和产品功能进行严格审查。数据综合优先考虑现有的高品质临床检验研究和真实世界证据。所有发现均经过三角验证和交叉检验，以协调不同的观点，并确保结论反映的是一致的趋势，而非孤立的观察。

在适当情况下，我们采取了分析保障措施，以应对医疗保健和地方政策环境的差异。我们明确阐述了方法论的局限性，尤其是在证据基础尚未成熟或实践模式快速变化的情况下。本研究遵循与专家合作和资料处理的伦理标准，以确保定性研究结果的保密性和完整性。

本文简要概述如何将技术进步与策略性要务结合，从而将基因组检测转化为持久的临床和商业性影响。

先进定序技术、液态生物检体创新和数位化解读工具的融合，彻底改变了肺癌基因组检测的临床格局。这些发展既带来了机会，也带来了挑战。机会包括能够更精准地选择治疗方案、支持适应性临床试验以及透过微创检测进行长期监测。同时，供应链管理、证据产生和与支付方的合作等挑战则需要策略远见。因此，决策者必须采取整合的观点，将技术投资、临床检验和商业化路径有机结合。

有效的应对措施应将营运韧性与实证商业化结合。透过多元化供应来源、投资开发小型化、低成本的检测方法，并透过严谨的研究证明其临床和经济价值，相关人员能够加快技术应用，同时降低政策和市场波动带来的风险。同时，尊重当地监管标准和医疗基础设施的区域策略对于将全球潜力转化为永续的临床成果至关重要。简而言之，肺癌精准医疗时代需要产业界、临床界和监管相关人员的共同努力，才能将技术能力转化为病患疗效的提升。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 利用血液样本进行早期检测可治疗肺癌突变的新型液态生物检体技术
• 整合人工智慧驱动的生物资讯平台，用于快速分析非小细胞肺癌患者的复杂基因组图谱
• 实施全面的次世代定序方案，以识别罕见的驱动突变和抗药性机制。
• 扩大ALK、ROS1和EGFR突变型非小细胞肺癌标靶治疗伴随诊断的核准
• 扩大分散式基因组检测服务，以改善偏远和医疗服务不足的患者群体获得检测的机会。
• 为进行性肺癌基因组检测实施报销框架和基于价值的定价模式

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 肺癌基因组检测市场（依技术划分）

• 萤光原位杂合反应
• 微阵列
• 次世代定序
  • 标靶定序
  • 全外EXOME定序
  • 全基因测序
• 即时聚合酵素链锁反应
• 桑格定序

第九章 肺癌基因组检测市场（依检测类型划分）

• 液态生物检体
  • 循环性肿瘤细胞
  • 循环肿瘤DNA
• 组织切片检查
  • 细针穿刺法
  • 组织切片

第十章 肺癌基因组检测市场（依应用领域划分）

• 伴随诊断
• 预测性测试
• 预后测试
• 治疗监测

第十一章 肺癌基因组检测市场（依最终用户划分）

• 学术研究机构
• 医院和诊断实验室
• 製药和生物技术公司

第十二章 肺癌基因组检测市场（依地区划分）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十三章 肺癌基因组检测市场（依组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十四章 各国肺癌基因组检测市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十五章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-La Roche AG
  • QIAGEN NV
  • Guardant Health, Inc.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • BioMerieux SA
  • NeoGenomics Laboratories, Inc.
  • Foundation Medicine, Inc.

The Lung Cancer Genomic Testing Market is projected to grow by USD 2.07 billion at a CAGR of 8.56% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 1.07 billion
Estimated Year [2025]	USD 1.16 billion
Forecast Year [2032]	USD 2.07 billion
CAGR (%)	8.56%

A comprehensive orientation to how technological advances and clinical integration are redefining lung cancer genomic testing and shaping care pathways

Lung cancer genomic testing now sits at the intersection of clinical urgency and technological capability, reshaping diagnostics, therapeutic decision-making, and translational research. As molecular insights increasingly determine targeted therapies and immunotherapy candidacy, clinicians and laboratories are adopting genomic assays to move from histology-based care to precision-guided treatment pathways. In consequence, previously discrete disciplines-pathology, molecular biology, bioinformatics, and clinical oncology-are converging to deliver integrated care pathways that reduce time to targeted therapy and enable more nuanced patient stratification.

Moreover, the testing landscape is evolving from single-gene assays to multi-gene panels and comprehensive genomic profiling that capture actionable mutations, copy number alterations, and complex genomic signatures. Complementing tissue-based approaches, minimally invasive alternatives such as blood-based testing are accelerating diagnostic workflows and improving patient access to serial monitoring. At the same time, regulatory clarity, payer engagement, and clinical guideline updates are beginning to align, making genomic testing a central component of standard care in many oncology networks. Taken together, these dynamics have created a new operating environment where technological differentiation, evidence generation, and operational resilience determine which organizations lead the next wave of clinical and commercial adoption.

How converging advances in sequencing, liquid biopsy, and digital bioinformatics are rapidly transforming diagnostic pathways and patient management in lung cancer care

The landscape of lung cancer genomic testing is undergoing several transformative shifts driven by advances in assay technology, data analytics, and care delivery models. Most notably, next generation sequencing has evolved from high-cost, research-oriented workflows toward more efficient, clinically validated platforms that support targeted sequencing panels as well as broader coverage through whole exome and whole genome approaches. This progression enables clinicians to detect rare variants and comprehensive genomic signatures while laboratories optimize throughput and turnaround time.

In parallel, liquid biopsy methodologies-encompassing both circulating tumor cells and circulating tumor DNA-are transitioning from complementary tools to integral components of diagnostic and monitoring strategies. These assays offer a less invasive route to capture tumor heterogeneity and to monitor treatment response or emergent resistance. Meanwhile, real time polymerase chain reaction and fluorescence in situ hybridization maintain important roles for specific, rapid biomarker detection, particularly where regulatory or payer frameworks favor established methods.

Concurrently, digital health and AI-driven bioinformatics have matured to support automated variant calling, clinical annotation, and decision support, thereby reducing interpretation bottlenecks and enabling scalable reporting across diverse clinical settings. Regulatory agencies are adapting guidance for companion diagnostics and complex genomic tests, and payers are increasingly evaluating clinical utility and value-based reimbursement pathways. Together, these shifts are creating a more integrated, data-rich ecosystem that rewards evidence generation, interoperability, and operational agility.

How recent tariff-driven supply chain pressures have reshaped procurement, manufacturing strategies, and commercial approaches for genomic diagnostics

Recent tariff adjustments enacted by national policymakers have introduced a renewed emphasis on supply chain resilience and procurement strategy within the diagnostic ecosystem. Because genomic testing relies on a global supply chain for reagents, sequencing instruments, plastic consumables, and specialized microfluidic components, any tariff-driven cost increases reverberate through laboratory operations, reagent procurement cycles, and capital equipment acquisition decisions. As a result, laboratories and diagnostic providers have had to reassess vendor contracts, inventory strategies, and capital planning to preserve service continuity and to maintain acceptable turnaround times.

In response, several stakeholders have explored alternative sourcing and local manufacturing partnerships to mitigate exposure to import levies and shipping volatility. Procurement teams are negotiating longer-term supply agreements and prioritizing suppliers with diversified production footprints to reduce single-source risk. At the same time, diagnostic developers are accelerating work on assay designs that reduce reagent volumes or substitute tariff-sensitive components, thereby lowering the operational impact of import duties.

From a clinical perspective, sustained cost pressure may slow the adoption of more expensive, comprehensive testing in some care settings unless offset by payer coverage or bundled contracting. Consequently, laboratories and device manufacturers are investing in health economic evidence and real-world utility studies to demonstrate cost-effectiveness and inform value-based arrangements. Overall, tariff-driven pressures are catalyzing a strategic reorientation toward supply-chain diversification, localized manufacturing, and commercially sustainable assay design.

Segment-focused insights showing how technology choices, specimen modalities, clinical applications, and end-user capabilities jointly determine adoption pathways and value propositions

A detailed segmentation perspective reveals nuanced adoption patterns across technology, test type, application, and end user categories that are shaping market opportunity and investment priorities. Within the technology dimension, assays range from fluorescence in situ hybridization and microarray platforms to real time polymerase chain reaction and Sanger sequencing; however, next generation sequencing has emerged as a pivotal technology with diverse configurations that include targeted sequencing panels for focused actionable alterations, whole exome sequencing for comprehensive coding-region analysis, and whole genome sequencing for the broadest possible variant detection and structural insight. Each configuration carries distinct trade-offs in sensitivity, breadth of coverage, turnaround time, and interpretive complexity.

Regarding test type, the domain divides between liquid biopsy and tissue biopsy modalities. Liquid biopsy comprises both circulating tumor cells and circulating tumor DNA approaches, offering minimally invasive sampling and superior feasibility for serial monitoring. Tissue biopsy remains essential for histopathologic assessment and includes fine needle aspiration techniques as well as traditional tissue sections used for immunohistochemistry and confirmatory molecular assays. These two sampling paradigms often play complementary roles in the diagnostic pathway, with diagnostic stewardship determining optimal sequencing of tests.

In terms of application, testing supports companion diagnostics that directly guide therapy selection, predictive testing to anticipate treatment response, prognostic testing to inform outcome expectations, and treatment monitoring to detect resistance or recurrence. Adoption intensity varies by clinical setting, evidence base, and payer alignment. Finally, end users encompass academic and research institutes that drive assay validation and translational studies, hospitals and diagnostic laboratories that deliver clinical testing at scale and manage patient workflows, and pharmaceutical and biotechnology companies that rely on robust genomic characterization to support drug development, companion diagnostic partnerships, and patient selection strategies. The interplay among these segments underscores the importance of tailored value propositions, from high-throughput clinical laboratory services to niche translational platforms supporting drug discovery.

Regionally differentiated adoption dynamics and infrastructure considerations that influence technology roll-out, reimbursement engagement, and strategic partnerships

Regional dynamics materially influence technology adoption, regulatory alignment, and commercial strategy, with distinct patterns emerging across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. In the Americas, a robust ecosystem of academic centers, integrated health systems, and diagnostic innovators has driven early clinical adoption of advanced genomic profiling and liquid biopsy testing. Reimbursement frameworks and large-scale clinical studies in this region have supported the integration of companion diagnostics into therapeutic pathways, while leading laboratories and commercial partners continue to invest in platform scalability and clinical validation programs.

Across Europe, the Middle East and Africa, the landscape is more heterogeneous, characterized by strong regulatory oversight in several countries alongside variability in access and infrastructure. European jurisdictions are increasingly harmonizing regulatory expectations for clinical evidence and companion diagnostics, and collaborative networks are advancing multicenter studies to address clinical utility questions. In contrast, access in some parts of the Middle East and Africa remains constrained by laboratory capacity and reimbursement barriers, prompting a focus on regional centers of excellence and public-private partnerships to extend advanced testing services.

In the Asia-Pacific region, rapid expansion in clinical capacity and manufacturing capabilities is evident alongside diverse payer environments. Several markets demonstrate high adoption rates for both sequencing platforms and liquid biopsy testing, supported by growing local diagnostics industries and targeted investments in genomics. Nevertheless, adoption is uneven, and strategic players often combine centralized high-complexity testing hubs with decentralized sample collection and digital reporting to bridge geographic and resource constraints. These regional distinctions underline the need for market entry strategies that reflect local regulatory processes, reimbursement pathways, and healthcare infrastructure.

How sequencing instrument makers, reagent suppliers, diagnostic laboratories, and biopharma partners are aligning strategies to gain clinical adoption and commercial differentiation

Competitive activity across the lung cancer genomic testing value chain is concentrated among companies that provide sequencing platforms, assay reagents, integrated diagnostic services, and clinical interpretation solutions, as well as among clinical laboratories and diagnostics developers who pair testing with therapeutic programs. Leading instrumentation providers have advanced platform roadmaps focused on throughput, run cost, and integrated analytics, while reagent and kit suppliers compete on robustness, lot-to-lot consistency, and clinical validation packages that simplify regulatory submissions and laboratory accreditation.

Diagnostic laboratories and specialty providers leverage vertical integration, offering end-to-end services from sample accessioning to clinical reporting, often augmenting their offerings with proprietary bioinformatics pipelines and curated variant databases. Pharmaceutical and biotechnology collaborators prioritize partners that can deliver rapid, reproducible genomic characterization to support patient selection in trials and companion diagnostic co-development. Strategic moves such as partnerships, distribution agreements, and targeted acquisitions are common as companies seek to broaden assay portfolios, enhance geographic footprint, and reduce time to market for diagnostic claims.

To remain competitive, organizations increasingly invest in real-world evidence generation, payor engagement, and interoperability with electronic health records to demonstrate clinical utility and to facilitate clinician adoption. Additionally, companies that offer scalable, cloud-enabled interpretation tools and that maintain high standards for clinical validation are best positioned to capture demand from both centralized reference laboratories and decentralized hospital networks.

Action-oriented recommendations for companies to strengthen supply resilience, accelerate evidence generation, and secure payer and partner alignment for sustainable growth

Industry leaders should prioritize a set of pragmatic, evidence-based actions to navigate technological complexity, policy shifts, and market pressures while capturing clinical and commercial value. First, diversify supply chains and pursue localized manufacturing or second-source agreements for tariff-sensitive reagents and consumables to reduce single-point vulnerabilities and to stabilize procurement costs. Parallel to this, invest in assay optimization that minimizes reagent volumes and streamlines workflows to preserve margins and resilience.

Second, accelerate clinical validation and real-world evidence programs that demonstrate clinical utility and health economic value. Robust outcome datasets will strengthen reimbursement negotiations and support placement of comprehensive genomic profiling in standard care pathways. Third, expand capabilities in bioinformatics and AI-driven interpretation to shorten report turnaround time, improve variant classification consistency, and enable scalable clinical decision support that integrates with electronic health systems. Fourth, cultivate payer relationships and explore value-based contracting that ties reimbursement to demonstrable clinical outcomes, thereby aligning incentives across stakeholders.

Fifth, form strategic partnerships with pharmaceutical developers to co-develop companion diagnostics and to secure trial enrollment through biomarker-driven screening. Finally, tailor market access strategies regionally by aligning product claims and evidence packages with local regulatory expectations and by deploying hybrid models that combine centralized high-complexity testing with facilitated sample logistics and remote reporting to broaden access.

A transparent multi-method research approach combining primary expert engagement and systematic evidence review to ensure rigorous and actionable insights

The research underlying this analysis employed a multi-method approach that combined primary qualitative inquiry with systematic secondary intelligence to build a robust and triangulated evidence base. Primary research included structured interviews with clinical laboratory directors, molecular pathologists, reimbursement specialists, diagnostic developers, and pharmaceutical R&D leaders, supplemented by expert panel discussions to validate emerging trends and practical challenges in assay deployment. These engagements provided granular insight into laboratory workflows, procurement dynamics, and the operational impact of regulatory and tariff changes.

Secondary research entailed a rigorous review of regulatory guidance documents, clinical practice recommendations, peer-reviewed literature on assay performance and utility, and corporate disclosures that elucidate strategic priorities and product capabilities. Data synthesis prioritized high-quality clinical validation studies and real-world evidence where available. All findings were cross-validated through triangulation to reconcile differing perspectives and to ensure that conclusions reflect consistent signals rather than isolated observations.

Where appropriate, analytical safeguards were applied to account for variability in care settings and regional policy environments. Methodological limitations were explicitly noted, particularly where evidence remains nascent or practice patterns are rapidly evolving. The research adhered to ethical standards for expert engagement and data handling, ensuring confidentiality and the integrity of qualitative insights.

A concise synthesis of how technological advances and strategic imperatives must be aligned to translate genomic testing into durable clinical and commercial impact

The convergence of advanced sequencing technologies, liquid biopsy innovations, and digital interpretation tools has irreversibly altered the clinical landscape for lung cancer genomic testing. These developments present both opportunities and challenges: opportunities to enable more precise treatment selection, to support adaptive clinical trials, and to deliver longitudinal monitoring with minimally invasive tests; and challenges in supply-chain management, evidence generation, and payer engagement that require strategic foresight. Decision-makers must therefore adopt an integrated view that aligns technological investment, clinical validation, and commercial pathways.

Effective responses will blend operational resilience with evidence-led commercialization. By diversifying supply sources, investing in compact and cost-efficient assays, and demonstrating clinical and economic value through robust studies, stakeholders can reduce exposure to policy and market shocks while accelerating adoption. At the same time, regionally nuanced strategies that respect local regulatory norms and healthcare infrastructures will be essential for converting global potential into sustainable clinical impact. In sum, the era of precision oncology in lung cancer depends on harmonized action across industry, clinical, and regulatory stakeholders to translate technical capability into improved patient outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Emergence of liquid biopsy assays for early detection of actionable lung cancer mutations using blood samples
• 5.2. Integration of AI-driven bioinformatics platforms for rapid analysis of complex genomic profiles in NSCLC patients
• 5.3. Adoption of comprehensive next generation sequencing panels to identify rare driver mutations and resistance mechanisms
• 5.4. Growth of companion diagnostic approvals for targeted therapies in ALK, ROS1, EGFR mutated non small cell lung cancer
• 5.5. Expansion of decentralized genomic testing services to improve accessibility in remote and underserved patient populations
• 5.6. Implementation of reimbursement frameworks and value-based pricing models for advanced lung cancer genomic tests

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Lung Cancer Genomic Testing Market, by Technology

• 8.1. Fluorescence In Situ Hybridization
• 8.2. Microarray
• 8.3. Next Generation Sequencing
  • 8.3.1. Targeted Sequencing
  • 8.3.2. Whole Exome Sequencing
  • 8.3.3. Whole Genome Sequencing
• 8.4. Real Time Polymerase Chain Reaction
• 8.5. Sanger Sequencing

9. Lung Cancer Genomic Testing Market, by Test Type

• 9.1. Liquid Biopsy
  • 9.1.1. Circulating Tumor Cells
  • 9.1.2. Circulating Tumor Dna
• 9.2. Tissue Biopsy
  • 9.2.1. Fine Needle Aspiration
  • 9.2.2. Tissue Section

10. Lung Cancer Genomic Testing Market, by Application

• 10.1. Companion Diagnostics
• 10.2. Predictive Testing
• 10.3. Prognostic Testing
• 10.4. Treatment Monitoring

11. Lung Cancer Genomic Testing Market, by End User

• 11.1. Academic And Research Institutes
• 11.2. Hospitals And Diagnostic Laboratories
• 11.3. Pharmaceutical And Biotechnology Companies

12. Lung Cancer Genomic Testing Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Lung Cancer Genomic Testing Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Lung Cancer Genomic Testing Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Analysis
  • 15.3.1. Illumina, Inc.
  • 15.3.2. Thermo Fisher Scientific Inc.
  • 15.3.3. F. Hoffmann-La Roche AG
  • 15.3.4. QIAGEN N.V.
  • 15.3.5. Guardant Health, Inc.
  • 15.3.6. Myriad Genetics, Inc.
  • 15.3.7. Natera, Inc.
  • 15.3.8. BioMerieux S.A.
  • 15.3.9. NeoGenomics Laboratories, Inc.
  • 15.3.10. Foundation Medicine, Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 11. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. EUROPEAN UNION LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. BRICS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. G7 LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. NATO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. LUNG CANCER GENOMIC TESTING MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 28. LUNG CANCER GENOMIC TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. LUNG CANCER GENOMIC TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR DNA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR DNA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR DNA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR DNA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE SECTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE SECTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE SECTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE SECTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE SECTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE SECTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PREDICTIVE TESTING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PREDICTIVE TESTING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PREDICTIVE TESTING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PREDICTIVE TESTING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PREDICTIVE TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PREDICTIVE TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PROGNOSTIC TESTING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PROGNOSTIC TESTING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PROGNOSTIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PROGNOSTIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PROGNOSTIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PROGNOSTIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TREATMENT MONITORING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TREATMENT MONITORING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TREATMENT MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TREATMENT MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 147. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 148. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 149. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 150. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 151. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
• TABLE 152. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
• TABLE 153. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 154. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 155. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
• TABLE 156. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2032 (USD MILLION)
• TABLE 157. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
• TABLE 158. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2032 (USD MILLION)
• TABLE 159. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 160. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 161. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 162. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 163. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 164. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 165. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 166. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 167. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
• TABLE 168. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
• TABLE 169. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 170. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 171. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
• TABLE 172. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2032 (USD MILLION)
• TABLE 173. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
• TABLE 174. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2032 (USD MILLION)
• TABLE 175. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 176. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 177. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 178. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 179. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 180. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 181. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 182. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 183. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
• TABLE 184. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
• TABLE 185. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 186. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 187. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
• TABLE 188. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2032 (USD MILLION)
• TABLE 189. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
• TABLE 190. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2032 (USD MILLION)
• TABLE 191. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 192. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 193. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 194. LATIN AMERICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 195. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 196. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 197. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 198. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 199. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
• TABLE 200. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
• TABLE 201. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2032 (USD MILLION)
• TABLE 205. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
• TABLE 206. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2032 (USD MILLION)
• TABLE 207. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 208. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 209. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 210. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 211. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 212. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 213. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 214. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 215. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
• TABLE 216. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
• TABLE 217. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 218. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 219. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
• TABLE 220. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2032 (USD MILLION)
• TABLE 221. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
• TABLE 222. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2032 (USD MILLION)
• TABLE 223. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 224. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 225. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 226. EUROPE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 227. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 228. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 229. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 230. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 231. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
• TABLE 232. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
• TABLE 233. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 234. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 235. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
• TABLE 236. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2032 (USD MILLION)
• TABLE 237. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
• TABLE 238. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2032 (USD MILLION)
• TABLE 239. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 240. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 241. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 242. MIDDLE EAST LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 243. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 244. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 245. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 246. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 247. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
• TABLE 248. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
• TABLE 249. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 250. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 251. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
• TABLE 252. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2032 (USD MILLION)
• TABLE 253. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
• TABLE 254. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2032 (USD MILLION)
• TABLE 255. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 256. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 257. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 258. AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 259. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 260. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 261. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 262. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 263. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
• TABLE 264. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
• TABLE 265. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 266. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 267. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
• TABLE 268. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2032 (USD MILLION)
• TABLE 269. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
• TABLE 270. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2032 (USD MILLION)
• TABLE 271. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 272. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 273. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 274. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 275. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 276. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 277. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 278. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 279. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 280. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 281. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
• TABLE 282. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
• TABLE 283. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 284. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 285. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2024 (USD MILLION)
• TABLE 286. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2025-2032 (USD MILLION)
• TABLE 287. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2024 (USD MILLION)
• TABLE 288. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2025-2032 (USD MILLION)
• TABLE 289. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 290. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 291. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 292. ASEAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 293. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 294. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 295. GCC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEC